Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies.

ABSTRACT:

Background

CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy stands out as a revolutionary intervention, exhibiting remarkable remission rates in patients with refractory/relapsed (R/R) B-cell malignancies. However, the potential side effects of therapy, particularly cytokine release syndrome (CRS) and infections, pose significant challenges due to their overlapping clinical features. Promptly distinguishing between CRS and infection post CD19 target CAR-T cell infusion (CTI) remains a clinical dilemma. Our study aimed to analyze the incidence of infections and identify key indicators for early infection detection in febrile patients within 30 days post-CTI for B-cell malignancies.

Methods

In this retrospective cohort study, a cohort of 104 consecutive patients

SUBMITTER: Pu LF 

PROVIDER: S-EPMC11221099 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature